| scholarly article | Q13442814 |
| P50 | author | Dieter Buchheidt | Q40279734 |
| P2093 | author name string | Wolf-Karsten Hofmann | |
| Mark Reinwald | |||
| Tobias Boch | |||
| P2860 | cites work | Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis | Q24316448 |
| Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage | Q24603171 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia | Q27266125 | ||
| Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study | Q27276774 | ||
| EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer | Q27851440 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. | Q27851723 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial | Q27852787 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q27852989 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 | ||
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials | Q27853120 | ||
| Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection | Q28504622 | ||
| Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages | Q28534361 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors | Q30317831 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study | Q30544631 | ||
| Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors | Q33344650 | ||
| Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma | Q33385283 | ||
| Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial | Q38160956 | ||
| Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors | Q38164667 | ||
| Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis | Q38167009 | ||
| Protein kinase inhibitors in renal cell carcinoma. | Q38170411 | ||
| Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia | Q38178192 | ||
| Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials | Q38195958 | ||
| Epidemiology of infections in cancer patients | Q38202569 | ||
| Protein kinase inhibitors to treat non-small-cell lung cancer | Q38205518 | ||
| Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia | Q38210132 | ||
| Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study | Q38279723 | ||
| Current treatment strategies for inhibiting mTOR in cancer | Q38286529 | ||
| BRAF and MEK inhibition in melanoma. | Q38342905 | ||
| FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. | Q38371186 | ||
| Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study | Q38375967 | ||
| The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. | Q38893121 | ||
| JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 | ||
| JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 | ||
| Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer | Q41370614 | ||
| Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening | Q41463007 | ||
| Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection | Q41636433 | ||
| Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy | Q41892625 | ||
| Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling | Q41963473 | ||
| Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial | Q42171624 | ||
| X-linked agammaglobulinemia: report on a United States registry of 201 patients | Q64377617 | ||
| Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis | Q84751886 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Temsirolimus | Q87733399 | ||
| Axitinib for renal cell carcinoma | Q94699157 | ||
| Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant | Q33390350 | ||
| Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. | Q33397085 | ||
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). | Q33398716 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial | Q33405554 | ||
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 | ||
| Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Q33411211 | ||
| Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma | Q33413834 | ||
| Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis | Q33416874 | ||
| Ruxolitinib: a review of its use in patients with myelofibrosis | Q33419865 | ||
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | Q33420037 | ||
| Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). | Q33420821 | ||
| Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu | Q33447149 | ||
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma | Q33690142 | ||
| Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia | Q33903030 | ||
| Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study | Q33990849 | ||
| Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production | Q34007875 | ||
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 | ||
| β-Arrestin 2 negatively regulates Toll-like receptor 4 (TLR4)-triggered inflammatory signaling via targeting p38 MAPK and interleukin 10. | Q34044736 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors | Q34163515 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Q34263959 | ||
| Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 | ||
| Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks | Q34316147 | ||
| A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Q34322740 | ||
| An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor | Q34343220 | ||
| Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency | Q34380652 | ||
| Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients | Q34401878 | ||
| Sorafenib: targeting multiple tyrosine kinases in cancer | Q34416659 | ||
| Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. | Q34434935 | ||
| The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience | Q34486116 | ||
| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia | Q34620246 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial | Q34638316 | ||
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q34645665 | ||
| A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). | Q34663617 | ||
| Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia | Q35008618 | ||
| Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. | Q35063446 | ||
| A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia | Q35132525 | ||
| Ibrutinib treatment ameliorates murine chronic graft-versus-host disease | Q35140097 | ||
| Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells | Q35144129 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. | Q35462692 | ||
| Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection | Q35515704 | ||
| Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia | Q35571035 | ||
| A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting | Q35591889 | ||
| Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma | Q35611909 | ||
| Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response | Q35889249 | ||
| Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. | Q36494245 | ||
| Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor | Q36654518 | ||
| Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors | Q36959193 | ||
| Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection | Q37117640 | ||
| Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. | Q37283112 | ||
| Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review | Q37566301 | ||
| Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. | Q37627806 | ||
| Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation | Q37667684 | ||
| Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma | Q37701147 | ||
| Epidemiology and Management of Infectious Complications of Contemporary Management of Chronic Leukemias | Q37779328 | ||
| Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. | Q37863795 | ||
| Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. | Q37957052 | ||
| Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study | Q37961390 | ||
| Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications | Q37977471 | ||
| A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor | Q38044248 | ||
| The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective | Q38140890 | ||
| Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients | Q42204004 | ||
| Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor | Q42208983 | ||
| Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment | Q42212297 | ||
| Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. | Q42232321 | ||
| Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase | Q42276725 | ||
| An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer | Q42635935 | ||
| Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies | Q42651946 | ||
| Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy | Q42956257 | ||
| Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. | Q43056663 | ||
| Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate | Q43281012 | ||
| The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
| Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party | Q43472495 | ||
| Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation | Q43539481 | ||
| Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor | Q43873032 | ||
| Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. | Q44358941 | ||
| Progressive multifocal leukoencephalopathy associated with ruxolitinib | Q44509111 | ||
| Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis | Q44518151 | ||
| Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). | Q44630703 | ||
| Bilateral toxoplasmosis retinitis associated with ruxolitinib | Q44909357 | ||
| Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner | Q45168860 | ||
| A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). | Q45272587 | ||
| Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation | Q45340125 | ||
| Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. | Q45350105 | ||
| Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment | Q45422025 | ||
| Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial | Q45842857 | ||
| Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. | Q45930884 | ||
| Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. | Q46004116 | ||
| Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Q46006772 | ||
| MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib | Q46135183 | ||
| Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens | Q46488793 | ||
| Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders | Q46513376 | ||
| Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia | Q46756876 | ||
| Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer | Q46757183 | ||
| High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group | Q46847866 | ||
| Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. | Q46969850 | ||
| Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial | Q47903403 | ||
| Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling | Q49291505 | ||
| Btk is a positive regulator in the TREM-1/DAP12 signaling pathway. | Q50335863 | ||
| The effect of sunitinib on immune subsets in metastatic clear cell renal cancer. | Q50537326 | ||
| Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. | Q50564383 | ||
| Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors. | Q51704257 | ||
| Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? | Q54393708 | ||
| Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. | Q54394851 | ||
| Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. | Q54504324 | ||
| Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. | Q54505605 | ||
| Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. | Q54539122 | ||
| The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. | Q54544974 | ||
| Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. | Q55044207 | ||
| Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma | Q57214428 | ||
| Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57570640 | ||
| P433 | issue | Suppl 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 55-68 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Biomarker Insights | Q4915072 |
| P1476 | title | Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors | |
| P478 | volume | 10 |
| Q50065065 | Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways |
| Q90609918 | Clinical Performance of (1,3) Beta-D Glucan for the Diagnosis of Pneumocystis Pneumonia (PCP) in Cancer Patients Tested With PCP Polymerase Chain Reaction |
| Q54109898 | Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. |
| Q91910045 | First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia |
| Q54117915 | Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses. |
| Q92355858 | New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies |
| Q64988558 | Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy. |
| Q48155956 | Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). |
| Q64061478 | Top-ten infections in onco-hematological patients (2015-2017) |
| Q40280368 | Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. |
Search more.